USING GENETIC INFORMATION TO SYNTHESIZE FUNCTIONAL GENE PRODUCTS / REVIEW ARTICLE
Keywords:
Gene expression, Functional Gene, Gene RegulationAbstract
We must answer some questions: What is gene expression? How does that happen? How is it diagnosed when talking about gene expression there is certainly a lot of information that may be missing or missed, were not able to reach it, as the rate of gene expression is linked to the rate of metabolic processes and the extent of the flow of all metabolites through certain pathways by regulating the formation or synthesis of specific enzymes for each gene, the rate of change in the activities of enzymes is present when essential substances are available. In contrast, enzymes required for biosynthesis are generally catabolic enzymes that are stimulated, catabolic enzymes are inhibited when metabolic products are present in the pathway in which they function
References
Brown, R.H.; Al-Chalabi, A. Amyotrophic Lateral Sclerosis. N. Engl. J. Med. 2017, 377, 162–172.
Feldman, E.L.; Goutman, S.A.; Petri, S.; Mazzini, L.; Savelieff, M.G.; Shaw, P.J.; Sobue, G. Amyotrophic Lateral Sclerosis. Lancet 2022, 400, 1363–1380.
Chiò, A.; Mora, G.; Moglia, C.; Manera, U.; Canosa, A.; Cammarosano, S.; Ilardi, A.; Bertuzzo, D.; Bersano, E.; Cugnasco, P. Secular Trends of Amyotrophic Lateral Sclerosis: The Piemonte and Valle d’Aosta Register. JAMA Neurol. 2017, 74, 1097–1104.
Tondo, G.; De Marchi, F. From Biomarkers to Precision Medicine in Neurodegenerative Diseases: Where Are We? J. Clin. Med. 2022, 11, 4515.
Vignaroli, F.; Mele, A.; Tondo, G.; De Giorgis, V.; Manfredi, M.; Comi, C.; Mazzini, L.; De Marchi, F. The Need for Biomarkers in the ALS–FTD Spectrum: A Clinical Point of View on the Role of Proteomics. Proteomes 2023, 11, 1.
Bang, J.; Spina, S.; Miller, B.L. Non-Alzheimer’s Dementia 1: Frontotemporal Dementia. Lancet 2015, 386, 1672.
Olney, N.T.; Spina, S.; Miller, B.L. Frontotemporal Dementia. Neurol. Clin. 2017, 35, 339–374.
Tondo, G.; De Marchi, F.; Terazzi, E.; Sacchetti, M.; Cantello, R. Frontotemporal Dementia Presenting as Gambling Disorder: When a Psychiatric Condition Is the Clue to a Neurodegenerative Disease. Cogn. Behav. Neurol. 2017, 30, 62–67.
Rascovsky, K.; Grossman, M. Clinical Diagnostic Criteria and Classification Controversies in Frontotemporal Lobar Degeneration. Int. Rev. Psychiatry 2013, 25, 145–158.
Rascovsky, K.; Hodges, J.R.; Knopman, D.; Mendez, M.F.; Kramer, J.H.; Neuhaus, J.; Van Swieten, J.C.; Seelaar, H.; Dopper, E.G.P.; Onyike, C.U. Sensitivity of Revised Diagnostic Criteria for the Behavioural Variant of Frontotemporal Dementia. Brain 2011, 134, 2456–2477.
Liljegren, M.; Naasan, G.; Temlett, J.; Perry, D.C.; Rankin, K.P.; Merrilees, J.; Grinberg, L.T.; Seeley, W.W.; Englund, E.; Miller, B.L. Criminal Behavior in Frontotemporal Dementia and Alzheimer Disease. JAMA Neurol. 2015, 72, 295–300.
Benussi, A.; Padovani, A.; Borroni, B. Phenotypic Heterogeneity of Monogenic Frontotemporal Dementia. Front. Aging Neurosci. 2015, 7, 171.
Burrell, J.R.; Halliday, G.M.; Kril, J.J.; Ittner, L.M.; Götz, J.; Kiernan, M.C.; Hodges, J.R. The Frontotemporal Dementia-Motor Neuron Disease Continuum. Lancet 2016, 388, 919–931.
De Marchi, F.; Tondo, G.; Sarnelli, M.F.; Corrado, L.; Solara, V.; D’Alfonso, S.; Cantello, R.; Mazzini, L. A Case of Progressive Non-Fluent Aphasia as Onset of Amyotrophic Lateral Sclerosis with Frontotemporal Dementia. Int. J. Neurosci. 2019, 129, 719–721.
Olszewska, D.A.; Lonergan, R.; Fallon, E.M.; Lynch, T. Genetics of Frontotemporal Dementia. Curr. Neurol. Neurosci. Rep. 2016, 16, 1–15.
Greaves, C.V.; Rohrer, J.D. An Update on Genetic Frontotemporal Dementia. J. Neurol. 2019, 266, 2075–2086
Mandrioli, J.; Zucchi, E.; Martinelli, I.; Van der Most, L.; Gianferrari, G.; Moglia, C.; Manera, U.; Solero, L.; Vasta, R.; Canosa, A. Factors Predicting Disease Progression in C9ORF72 ALS Patients. J. Neurol. 2023, 270, 877–890.
Mazzini, L.; Ferrari, D.; Andjus, P.R.; Buzanska, L.; Cantello, R.; De Marchi, F.; Gelati, M.; Giniatullin, R.; Glover, J.C.; Grilli, M.; et al. Advances in Stem Cell Therapy for Amyotrophic Lateral Sclerosis. Expert. Opin. Biol. Ther. 2018, 18, 865–881.
De Marchi, F.; Franjkic, T.; Schito, P.; Russo, T.; Nimac, J.; Chami, A.A.; Mele, A.; Vidatic, L.; Kriz, J.; Julien, J.-P. Emerging Trends in the Field of Inflammation and Proteinopathy in ALS/FTD Spectrum Disorder. Biomedicines 2023, 11, 1599.
Grassano, M.; Calvo, A.; Moglia, C.; Sbaiz, L.; Brunetti, M.; Barberis, M.; Casale, F.; Manera, U.; Vasta, R.; Canosa, A. Systematic Evaluation of Genetic Mutations in ALS: A Population-Based Study. J. Neurol. Neurosurg. Psychiatry 2022, 93, 1190–1193.
Riva, N.; Pozzi, L.; Russo, T.; Pipitone, G.B.; Schito, P.; Domi, T.; Agosta, F.; Quattrini, A.; Carrera, P.; Filippi, M. NEK1 Variants in a Cohort of Italian Patients with Amyotrophic Lateral Sclerosis. Front. Neurosci. 2022, 16, 833051.
Chia, R.; Chiò, A.; Traynor, B.J. Novel Genes Associated with Amyotrophic Lateral Sclerosis: Diagnostic and Clinical Implications. Lancet Neurol. 2018, 17, 94–102.
Van Swieten, J.C.; Heutink, P. Mutations in Progranulin (GRN) within the Spectrum of Clinical and Pathological Phenotypes of Frontotemporal Dementia. Lancet Neurol. 2008, 7, 965–974.
Wang, X.; Zeng, P.; Fang, Y.; Zhang, T.; Tian, Q. Progranulin in Neurodegenerative Dementia. J. Neurochem. 2021, 158, 119–137.
Simon, M.J.; Logan, T.; DeVos, S.L.; Di Paolo, G. Lysosomal Functions of Progranulin and Implications for Treatment of Frontotemporal Dementia. Trends Cell Biol. 2022, 33, 324–339.
Strang, K.H.; Golde, T.E.; Giasson, B.I. MAPT Mutations, Tauopathy, and Mechanisms of Neurodegeneration. Lab. Investig. 2019, 99, 912–928.
Virgilio, E.; De Marchi, F.; Contaldi, E.; Dianzani, U.; Cantello, R.; Mazzini, L.; Comi, C. The Role of Tau beyond Alzheimer’s Disease: A Narrative Review. Biomedicines 2022, 10, 760.
Balendra, R.; Isaacs, A.M. C9orf72-Mediated ALS and FTD: Multiple Pathways to Disease. Nat. Rev. Neurol. 2018, 14, 544–558.
Satsavayai, S.C.; Nana, A.L.; Yokoyama, J.S.; Seeley, W.W. C9orf72-FTD/ALS Pathogenesis: Evidence from Human Neuropathological Studies. Acta Neuropathol. 2019, 137, 1–26.
Smeyers, J.; Banchi, E.-G.; Latouche, M. C9ORF72: What It Is, What It Does, and Why It Matters. Front. Cell Neurosci. 2021, 15, 661447.
Farg, M.A.; Sundaramoorthy, V.; Sultana, J.M.; Yang, S.; Atkinson, R.A.K.; Levina, V.; Halloran, M.A.; Gleeson, P.A.; Blair, I.P.; Soo, K.Y.; C9ORF72, Implicated in Amytrophic Lateral Sclerosis and Frontotemporal Dementia, Regulates Endosomal Trafficking. Hum. Mol. Genet. 2014, 23, 3579–3595.
Gendron, T.F.; Petrucelli, L. Disease Mechanisms of C9ORF72 Repeat Expansions. Cold Spring Harb. Perspect. Med. 2018, 8, a024224.
Kwon, H.S.; Koh, S.-H. Neuroinflammation in Neurodegenerative Disorders: The Roles of Microglia and Astrocytes. Transl. Neurodegener. 2020, 9, 1–12.
Stephenson, J.; Nutma, E.; van der Valk, P.; Amor, S. Inflammation in CNS Neurodegenerative Diseases. Immunology 2018, 154, 204–219.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
